Ubiquitin-mediated protein degradation is the main mechanism for controlled proteolysis, which is crucial for muscle development and maintenance. The ankyrin repeat-containing protein with a suppressor of cytokine signaling box 2 gene (ASB2) encodes the specificity subunit of an E3 ubiquitin ligase complex involved in differentiation of hematopoietic cells. Here, we provide the first evidence that a novel ASB2 isoform, ASB2b, is important for muscle differentiation. ASB2b is expressed in muscle cells during embryogenesis and in adult tissues. ASB2b is part of an active E3 ubiquitin ligase complex and targets the actin-binding protein filamin B ( The ubiquitin-proteasome system (UPS) is one of the major mechanisms for controlled proteolysis, which is a crucial determinant of many cellular events in eukaryotes. Degradation of a protein by the ubiquitin-proteasome pathway entails two successive events: the covalent attachment of ubiquitin chains to lysine residues in a substrate protein leading to its recognition and ATP-dependent proteolysis by the proteasome. Ubiquitylation of protein substrates occurs through the sequential action of distinct enzymes: a ubiquitin-activating enzyme E1, a ubiquitin-conjugating enzyme E2 and a ubiquitin ligase E3 responsible for the specific recognition of substrates through dedicated interaction domains.
The ubiquitin-proteasome system (UPS) is one of the major mechanisms for controlled proteolysis, which is a crucial determinant of many cellular events in eukaryotes. Degradation of a protein by the ubiquitin-proteasome pathway entails two successive events: the covalent attachment of ubiquitin chains to lysine residues in a substrate protein leading to its recognition and ATP-dependent proteolysis by the proteasome. Ubiquitylation of protein substrates occurs through the sequential action of distinct enzymes: a ubiquitin-activating enzyme E1, a ubiquitin-conjugating enzyme E2 and a ubiquitin ligase E3 responsible for the specific recognition of substrates through dedicated interaction domains.
1 ASB2 is one of 18 members of the ankyrin repeat-containing suppressor of cytokine signaling (SOCS) box protein family (ASB) that are characterized by variable numbers of N-terminal ankyrin repeats. 2 The ASB2 gene was originally identified as an retinoic acid-inducible gene involved in induced differentiation of myeloid leukemia cells. 3, 4 We have previously demonstrated that, by interacting with the elongin BC complex, ASB2 can assemble with a Cullin5/Rbx module to form an E3 ubiquitin ligase complex that stimulates polyubiquitylation by the E2 ubiquitin-conjugating enzyme UbcH5a. 5, 6 This strongly suggests that ASB2 targets specific proteins to destruction by the proteasome during differentiation of hematopoietic cells. We have recently shown that ASB2 ubiquitin ligase activity drives proteasome-mediated degradation of the ubiquitously expressed actin-binding protein filamins (FLNs), FLNa and b, and can regulate integrin-mediated cell spreading. 6 During muscle development, dramatic changes in protein expression and cell morphology rely on the turnover of regulatory and structural components. Indeed, myogenic transcription factors such as MyoD and its E2A partner or negative Id regulator as well as myofibrillar proteins were shown to be degraded by the UPS. [7] [8] [9] [10] [11] Although some E3 ubiquitin ligases active during myogenesis have been identified, 12 -23 a precise understanding of the function of ubiquitylation in muscle development and the identities of specific ubiquitin ligases and their potential substrates is lacking.
Here we show that ASB2 expression is not restricted to hematopoietic cells but is also expressed and regulated in muscle cells during mouse and chick embryogenesis.
Furthermore, ASB2 transcripts expressed in muscle cells encode for a novel ASB2 isoform that we have named ASB2b. Its expression is induced during myogenic differentiation of C2C12 and primary myoblasts. By interacting with the elongin BC complex, ASB2b can assemble with the Cullin5/Rbx2 module to reconstitute an active E3 ubiquitin ligase complex and we show that ASB2b triggers ubiquitylation and drives proteasomal degradation of FLNb but not of FLNa. Knockdown of ASB2b expression markedly delayed FLNb degradation and decreased C2C12 differentiation. Thus, our study provides the first evidence that FLNb regulation, through proteasomal degradation pathways, may regulate muscle differentiation.
Results
ASB2 is expressed in developing and mature muscle cells. ASB2 is known to be expressed in hematopoietic cells, where it is important for cell differentiation. 3, 6 To examine whether ASB2 may have functions outside the hematopoietic system, we examined expression of ASB2 mRNA in a variety of other tissues. Human ASB2 mRNA was detected in bone marrow, skeletal muscle, heart, fetal heart, small intestine, appendix, bladder, aorta, stomach, uterus, prostate, colon and thyroid gland ( Figure 1a ). Human ASB2 transcripts were relatively less abundant in tissues containing nonstriated muscle than in skeletal and cardiac muscle. ASB2 expression was induced during mouse embryonic development ( Figure 1b ) and its expression was maintained in skeletal muscle and heart in the adult mice ( Figure 1c) . To examine the expression of ASB2 during chick embryogenesis, we performed in situ hybridization to whole-mount embryos and to tissue sections at various stages of development ( Figure 2 ). In situ hybridization to whole-mount embryos showed an expression of ASB2 in the somites (Figure 2a-c and e) , and in the heart (Figure 2c and g) from E3 and in the limb (Figure 2d ) from E6. In situ hybridization to tissue sections showed that the somitic expression of ASB2 corresponds to the myotome (Figure 2e ). ASB2 transcripts are detected in all the heart (Figure 2g ). An additional site of ASB2 expression was observed in smooth muscle cells of the intestine at E6 (Figure 2f) . Finally, the limb ASB2 expression corresponds to skeletal muscle expression (Figure 2d and h ). Altogether these results demonstrated that ASB2 is developmentally regulated and that its expression previously described in hematopoiesis is also associated with the formation of all types of muscles, including skeletal, smooth and cardiac muscles.
ASB2 is induced during myogenic differentiation. Because myogenic differentiation can be recapitulated in vitro, wherein myoblasts can be converted to myotubes, we examined the expression of ASB2 mRNA throughout the well-established differentiation model of the C2C12 mouse cell line. Differentiation of C2C12 cells was confirmed by their morphological changes such as alignment, elongation and fusion of mononucleated cells to multinucleated myotubes after switching cells from growth medium (GM) to differentiation medium (DM) (Figure 3a ). Accompanying these morphological changes, the expression of muscle-specific proteins, myogenin, myosin heavy chain (MHC) and troponin T was upregulated (Figure 3b and c) . The ASB2 transcripts were barely detectable in undifferentiated C2C12 cells, increased in cells cultured in DM for 8 h and were continuously expressed until day 8 ( Figure 3d ). By this time, myogenin, an early marker for the entry of myoblast into the differentiation, was induced To confirm RNA loading and integrity, we used b-actin as a probe (b) or methylene blue-stained 18S rRNA on membrane after transfer (c) (Figure 3b ), suggesting that ASB2 upregulation may coincide with the differentiation commitment of myoblasts. Altogether, our results show that ASB2 is induced during myogenic differentiation.
ASB2b, a novel ASB2 isoform. The cDNA sequences encoding mouse ASB2 proteins were first analyzed in EST databases. Two different isoforms, a hematopoietic type and a muscle type, of ASB2 were identified and named ASB2a and ASB2b, respectively (Figure 4a ). The human ASB2a has been previously published. 3, 5 The mouse ASB2a was recently described in UniProtKB/Swiss-Prot database (release 12.0/54.0) as isoform 2 of Q8K0L0 whereas mouse ASB2b corresponds to isoform 1 of Q8K0L0. To confirm the expression of two ASB2 mRNAs, we performed quantitative RT-PCR experiments by amplification of cDNAs from skeletal muscle, heart, smooth muscle and hematopoietic cells with primers specific to ASB2a, ASB2b or with primers common to both cDNAs. As shown in Figure 4b , ASB2b mRNAs were mainly expressed in muscle Figure 2 Expression pattern of ASB2 during chick embryogenesis. ASB2 mRNAs were detected in whole-mount preparations (a-d) and sections through the trunk region (e), the intestine (f), the heart (g) or the developing limb skeletal muscle (g) of chick embryos by in situ hybridization. In each panel, the developmental stage is indicated. NT, neural tube; No, notochord; Dm, dermomyotome; My, myotome. Arrows indicate somites in a-c and e, limb skeletal muscle in d and h, and smooth muscle cells of the intestine in f. Arrowhead points to the heart cells whereas ASB2a mRNAs were expressed in hematopoietic cells. The new b isoform of ASB2 retains ankyrin repeats and the SOCS box (Figure 4a ). In addition, ASB2b harbors a ubiquitin-interacting motif (UIM) at its N terminus (Figure 4a and b) . The ASB2 SOCS box can be further divided into a BC box that defines a binding site for the elongin BC complex and a Cullin5 box that determines the binding specificity for Cullin5 5, 24 (Figure 4c ). ASB2a and ASB2b are predicted to have molecular weights of 64 and 70 kDa, respectively (Figure 4a ). To extend and further validate the finding that the ASB2b isoform is expressed in muscle cells, we raised anti-peptide polyclonal antibodies against an epitope within the N-terminal extension of ASB2b (2PNAB1 serum) or against an epitope within the C terminus common to both ASB2 isoforms (1PLA serum) (Figure 4a ). Flag-tagged ASB2 isoforms were expressed in HeLa cells to test the specificity of the antibodies by western blot analysis. As expected, anti-ASB2 antibodies from the 1PLA serum recognized both ASB2a and ASB2b isoforms whereas the anti-ASB2b antibodies from the 2PNAB1 serum recognized only the ASB2b isoform (Figure 4d) Relative expression of ASB2 mRNAs in human skeletal muscle, heart, smooth muscle and myeloid cells. Quantitative real-time RT-PCR was carried out as described in Materials and Methods section. Results are plotted as relative expression for ASB2a and ASB2b. Data corresponding to one out of three independent experiments are shown as mean ± standard deviation. (c) Alignments of the ubiquitin-interacting motif (UIM), the BC box and the Cullin5 box of mouse ASB2b with the consensus sequences. Shaded regions represent residues identical (black) or similar (gray) to the domain class consensus sequences. e is a negatively charged residue, F represents hydrophobic residue and x is any amino acid. In a and b, amino-acid numbering is indicated. (d) Isoform specificity of ASB2-specific antibodies. HeLa cells were transfected with Flag-tagged ASB2b and ASB2a expression vectors or the corresponding empty vector (À). Urea soluble fractions (5 mg) were separated by SDS-PAGE and subjected to immunoblotting with anti-Flag antibodies and 1PLA or 2PNAB1 serum, as indicated. (e) ASB2b protein is induced during differentiation of C2C12 myoblasts. C2C12 cells were cultured in GM and were shifted to DM for 2 and 4 days. Aliquots (30 mg) of each urea soluble fraction were analyzed by western blot using the 2PNAB1 serum. (f) ASB2b associated with elongins B and C, Cullin5 and Rbx2. Sf21 cells were infected with baculoviruses expressing the proteins indicated. The lysates were immunoprecipitated (IP) with anti-Flag antibodies. Crude extracts (input) and immune complexes were separated by SDS-PAGE and immunoblotted with the indicated antibodies. ASB2 isoforms were detected using the 1PLA serum. (g and h) The ASB2b/elongin BC/Cullin5/Rbx2 complex had ubiquitin ligase activity. The cell lysates of f were subjected to anti-Flag immunoaffinity purification. The purified ASB2 complexes were incubated with Uba1, UbcH5a, ubiquitin and ATP to assess their ability to stimulate ubiquitylation by UbcH5a by western blot using anti-polyubiquitin (g), anti-Flag (h, left panel) and anti-HA (h, right panel) antibodies. Arrow indicates the heavy chain of immunoglobulins (Ig(H)) the 2PNAB1 serum (Figure 4e ), indicating that ASB2b protein is induced during skeletal muscle differentiation.
ASB2b is the specificity subunit of an E3 ubiquitin ligase complex. Given that ASB2a is the specificity subunit of an E3 ubiquitin ligase complex and that ASB2b contains both BC and Cullin5 boxes, we determined whether ASB2b can also assemble with elongin B, elongin C and a Cullin5/Rbx module to reconstitute an E3 ubiquitin ligase complex. Therefore, anti-Flag immunoprecipitations were carried out on lysates of Sf21 cells coinfected with baculoviruses encoding Flag-ASB2b, elongin B, HSV-elongin C, Rbx2 4f). Similar to ASB2a, ASB2b can interact with elongin B, elongin C, Cullin5 and Rbx2 whereas an ASB2b BC-box mutant (ASB2bLA) did not ( Figure 4f ). To determine whether the ASB2b/elongin BC/Cullin5/Rbx2 complex possesses ubiquitin ligase activity, we immunoaffinity-purified and assayed the complex for its ability to activate formation of polyubiquitin chains by the E2 ubiquitin-conjugating enzyme UbcH5a in the presence of ATP, E1 ubiquitin-activating enzyme Uba1 and ubiquitin. As shown in Figure 4g , the ASB2b complex stimulated formation of ubiquitin conjugates by E2. In contrast, anti-Flag immunoprecipitation from lysates of insect cells not expressing ASB2b did not support formation of polyubiquitin conjugates (Figure 4g ). Furthermore, the ASB2b BC-box mutant that cannot assemble with elongin B, elongin C, Cullin5 and Rbx2 did not stimulate the polyubiquitylation activity of UbcH5a (Figure 4g ). Among the proteins that were polyubiquitylated in this in vitro ubiquitylation reaction, ASB2b and Cullin5 were found to be polyubiquitylated ( Figure 4h ). Altogether, our results indicated that ASB2b can assemble with elongin B, elongin C, Cullin5 and Rbx2 to reconstitute an active E3 ubiquitin ligase complex.
ASB2b triggers ubiquitylation and proteasome degradation of FLNb. We previously reported that ASB2a targets FLNa and FLNb to proteasome degradation. 6 We therefore assessed the expression of the ubiquitously expressed FLNa and FLNb as well as the muscle-specific FLNc during differentiation of C2C12 cells. Interestingly, ASB2b upregulation correlated with loss of FLNb (Figure 5a ). In contrast, expression of FLNa was not regulated and expression of FLNc was induced ( Figure 5a ). As shown in Figure 5b , accelerated degradation of FLNb was observed in differentiating C2C12 cells compared to proliferating cells. Furthermore, loss of FLNb was mediated by the proteasome as treatment of differentiating C2C12 cells with the proteasome inhibitor MG132 reduced FLNb degradation (Figure 5c ). Altogether, these suggest that FLNb may be a substrate of ASB2b. To determine whether ASB2b can promote FLNb ubiquitylation, we performed in vitro substrate ubiquitylation assays using purified GFP-tagged FLNb. When FLNb-GFP was used as a substrate, ubiquitylation of FLNb by UbcH5a in the presence of the ASB2b/elongin BC/Cullin5/Rbx2 or the ASB2a/elongin BC/Cullin5/Rbx2 complexes but not in the presence of ASB2 E3 ligase defective mutants (ASB2bLA or ASB2aLA) was observed (Figure 5d ). To confirm these results, we co-transfected NIH3T3 cells with vectors expressing GFP, GFP-ASB2b, GFP-ASB2bLA, GFP-ASB2a or GFP-ASB2aLA together with a FLNb-GFP or a FLNa-GFP expression vector. At 24 h after transfection, western blotting revealed that GFP-ASB2b expression resulted in a loss of FLNb-GFP (Figure 5e ) but not of FLNa-GFP (Figure 5f ). However, loss of both FLNa-GFP and FLNb-GFP was observed in cells transfected with a GFP-ASB2a expression vector as previously reported. 6 Furthermore, FLNb-GFP levels were not altered in cells expressing GFP-ASB2bLA (Figure 5e ). As expected, proteasome inhibitors blocked FLNb-GFP degradation induced by GFP-ASB2b (Figure 5e ). To determine whether ASB2b induces degradation of endogenous FLNb, we transfected C2C12 myoblasts with vectors expressing GFP-ASB2b or GFP-ASB2bLA. At 20 h after transfection, FLNb could not be detected in cells expressing GFPASB2bwt whereas FLNb expression was unaffected by GFP-ASB2bLA (Figure 5g ). To extend and further validate the finding that ASB2b induced FLNb degradation during myogenic differentiation, we investigated ASB2b and FLNb expression during differentiation of human primary myoblasts. Differentiation was confirmed by their morphological changes (Figure 6a ) and the expression of myogenin, MHC and troponin T (Figure 6b ) after switching cells from GM to DM. In these cells, ASB2b upregulation correlated with decrease of FLNb (Figure 6b) . Altogether, our results indicate that ASB2b ubiquitin ligase activity drives ubiquitin-mediated proteasomal degradation of FLNb.
Inhibition of ASB2b expression blocks myoblast fusion and myotube formation. To determine whether ASB2b is required for myoblast differentiation, we generated ASB2b knockdown stable cell populations by transfection of vectors encoding short-hairpin RNAs (shRNAs) directed against ASB2b. Knockdown of ASB2b expression in C2C12 cells cultured in DM was demonstrated by northern blot (data not shown) and western blot (Figure 7a and b) analyses. In these cells, FLNb degradation was delayed (Figure 7a and b) . Knockdown of ASB2b expression delayed myotube formation as evaluated by morphological observations (Figure 7c ) and confirmed by the reduction in the level of both MHC and troponin T expression (Figure 7f ). Furthermore, quantification of the fusion index demonstrated that ASB2b is required for myotube formation (Figure 7d and e) . Conversely, the cell population transfected with an empty vector formed myotubes and expressed markers of muscle differentiation upon a shift to DM as expected (Figure 7c-f (Figure 7h) . Altogether, our results indicated that ASB2b is required for the differentiation of C2C12 myoblasts into myotubes and regulates cell differentiation through FLNb degradation.
Discussion
The ASB2 gene was originally identified as a retinoic acid-inducible gene whose expression recapitulates early differentiation events critical to induced differentiation of myeloid leukemia cells. 3 ASB2b drives proteasomal degradation of filamin B NF Bello et al promoters resulting in the synthesis of two cell-specific ASB2 isoforms is the subject of ongoing experiments. We further demonstrate that ASB2b-specific antibodies recognize a 70 kDa protein in differentiated muscle cells. The two ASB2 isoforms differ in their N-terminal region but share ankyrin repeats and an SOCS box. As demonstrated for ASB2a, ASB2b, by interacting with the elongin BC complex, can assemble with Cullin5 and Rbx2 to form a bona fide multimeric really interesting new gene (RING)-type E3 ubiquitin ligase complex that stimulates polyubiquitylation by the E2 ubiquitin-conjugating enzyme UbcH5a. The ASB2b isoform harbors a UIM at its N terminus. The UIM was initially identified in the proteasomal S5a subunit as involved in recognition of ubiquitylated substrates. 25 UIMs form a single a-helix that binds polyubiquitin chains as well as monoubiquitin and promotes ubiquitylation of proteins that contain them. 26 Recently, the UIM motif of Met4 was shown to protect polyubiquitylated Met4 from proteolysis by the proteasome. 27 Whether ASB2 UIM is involved in the regulation of ASB2 stability and/or activity remains to be determined.
Although it is known that ASB proteins are implicated in diverse biological functions such as hematopoiesis, the substrates that are targeted for polyubiquitylation by ASB proteins are largely undefined. Although ASB2a induces proteasomal degradation of both FLNa and FLNb (Heuze et al.
6
; this report), we showed here that ASB2b induces FLNb ubiquitylation and subsequently FLNb degradation, indicating that ASB2b is specific for FLNb over FLNa. Furthermore, knockdown of endogenous ASB2b in C2C12 cells delays myogenic differentiation and FLNb degradation. These results are in line with the previously reported FLNb downregulation during C2C12 myoblast differentiation. 28 Because loss of FLNb is markedly delayed in ASB2b KD2 cells, we cannot exclude that a threshold of ASB2b is necessary to target FLNb to proteasomal degradation. Furthermore, we cannot exclude the possibility that other ASB2b targets are also important for differentiation of C2C12 cells.
Cell migration is a crucial step in skeletal muscle development during which myogenic progenitors migrate from the somites to the limb musculature. To differentiate and fuse to form syncytial skeletal muscle fibers, myoblasts must become less motile and establish cell-cell and cell-extracellular matrix contacts leading to cytoskeletal rearrangements. 29 In this regard, it is noteworthy that ASB2 is expressed in the myotome of the somites and in the limb during chick embryogenesis. This together with the fact that ASB2b can regulate the degradation of FLNb, a protein involved in actin remodeling, suggest that ASB2b can contribute to cytoskeletal reorganization during myogenesis. The appearance of ASB2b marks a very early event in differentiation of C2C12 cells; ASB2b was upregulated at the same time as myogenin, the earliest known marker of myoblasts committed to the differentiation pathway expressed before the establishment of the postmitotic state. 30 Inactivation of ASB2b by shRNAs interfered with the normal induction of muscle-specific proteins in C2C12 cells and delayed myotube formation. This suggests that ASB2b is important for myogenic differentiation. Furthermore, a partial knockdown of FLNb in ASB2b knockdown C2C12 cells accelerated the induction of differentiation markers, demonstrating that the cell differentiation defect of ASB2 knockdown cells is due, at least in part, to its effect on FLNb degradation.
Interestingly, ASB2b induction and subsequent FLNb downregulation correlates with the switch of the b1A to the b1D splice variant of the integrin b1 subunit associated with the commitment to differentiation of C2C12 myoblasts. A critical function of integrins during myogenesis has been proposed since antibody ligation of b1 integrins perturbed myotube formation in vitro 31 and inactivation of the mouse b1 integrin gene in developing myoblasts inhibited myoblast fusion and sarcomere assembly. 32 Previous reports have indicated that FLNb binds strongly to b1A integrin but poorly to b1D whereas talin binds strongly to b1D and with intermediate affinity to b1A. 28, 33 Thus, differential binding of FLNb or talin to b1A integrin may modulate integrin-dependent functions such as cytoskeleton remodeling and signaling. It is therefore tempting to speculate that ASB2b may impact integrindependent functions. Our results provide a mechanism through which expression of FLNb and integrins are coordinately regulated, allowing myogenic differentiation. Alternatively, because FLNs act as scaffolds for signaling molecules involved in actin remodeling and/or transcriptional regulation, ASB2b may regulate pathways downstream of FLNb that have to be activated during muscle differentiation. Which signal transduction pathways are regulated is the subject of ongoing investigation.
Expression of ASB2 in axial and limb skeletal muscles during chick embryogenesis is consistent with ASB2b expression in myotubes. ASB2b is expressed in adult muscles suggesting that ASB2b may also have a function in muscle remodeling. Interestingly, ASB2b is upregulated during mouse embryonic development at 17 d.p.c., a period associated with synaptic connections. Hence, it will be important to determine whether ASB2b expression correlates with muscle innervation. Furthermore, in a recent work aimed to the identification of transcripts with a circadian pattern of expression in adult skeletal muscle, atrogin-1, MURF1 as well as ASB2 were found to be circadian genes, 34 suggesting that these E3 ubiquitin ligases have a function in maintaining cellular homeostasis in skeletal muscle cells. An interesting possibility is that ASB2b regulates independent mechanisms in myoblasts and skeletal myotubes. In this regard, it will be important to identify ASB2b substrate(s) in fully differentiated muscle cells. Future studies will also be necessary to further our understanding of FLNb function in myoblasts.
Materials and Methods
Cell lines, culture conditions, induction and differentiation. The mouse myoblasts of the C2C12 cell line were grown in Dulbecco's modified Eagle's medium (DMEM) containing 4.5 g/l glucose, 10% fetal bovine serum (PAA Laboratories), 1% sodium pyruvate, 1% nonessential amino acids and penicillinstreptomycin (Invitrogen). For differentiation studies, C2C12 cells were plated at 7500 cells per cm 2 , grown to 80% confluence in 2 days and then cultured in differentiation medium containing DMEM supplemented with 2% horse serum (PAA Laboratories). Differentiation medium was changed every 48 h. The fusion index, that is, the number of nuclei in troponin T positive multinucleated myotubes divided by the total number of nuclei, calculated for C2C12 parental cells at day 6 was 65%. Human primary myoblasts isolated from a quadriceps muscle biopsy of a newborn infant as described 35 were obtained from V Mouly (Institut de Myologie, Paris, France). Human myoblasts were grown in F10 medium (Invitrogen) supplemented with 20% fetal bovine serum and penicillin-streptomycin. For differentiation studies, human myoblasts were plated at 3500 cells per cm 2 , grown to 80% confluence in 6 days and then cultured in differentiation medium containing DMEM supplemented with 10 mg/ml insulin (Sigma-Aldrich) and 100 mg/ml transferin (Sigma-Aldrich). Differentiation medium was changed every 24 h. HeLa cells were grown on Petri dishes in DMEM containing 4.5 g/l glucose, 10% fetal bovine serum (PAA Laboratories), glutamax, pyruvate and penicillin-streptomycin (Invitrogen). NIH3T3 cells were grown in DMEM containing 4.5 g/l glucose (Invitrogen), 1% sodium pyruvate, 10% newborn calf serum (PAA Laboratories) and penicillin-streptomycin. NB4 cells were used as described. 3 Cells were maintained in a 5% CO 2 incubator at 371C. For proteasome inhibition, NIH3T3 and C2C12 cells were incubated with 1 and 5 mM MG132 (Euromedex), respectively. To inhibit de novo protein synthesis, we treated C2C12 cells with 5 mg/ml cycloheximide (Sigma-Aldrich).
Plasmid constructs. The pCMVSport6-mASB2b vector was obtained from RZPD (Deutsches Ressourcenzentrum für Genomforschung GmbH). The mASB2b open-reading frame was subcloned into a pBacPAK9 (Clontech)-derived vector to direct the expression of mASB2b fused to the Flag epitope at its N terminus (pBacPAK9FN-mASB2b), into a pCMV-derived vector to direct the expression of mASB2b tagged with two Flag epitopes at its N terminus (pCMV-Flag2-mASB2b) and into the pEGFP-C3 expression vector (Clontech). Mutation L595A was introduced into mASB2b using the QuikChange site-directed mutagenesis kit (Stratagene) and the mutated oligonucleotide sequence, as indicated in boldface, 5 0 -CTCCGAGACCTGCGGCTCACCTCTGCCG-3 0 . The pcDNA3-cASB2 plasmid was obtained from the University of Delaware and contains the 3 0 end of chicken ASB2 cDNA (accession number AI982288). The hASB2a open-reading frame 3, 4 was subcloned into the pCMV-Flag2 generating the pCMV-Flag2-ASB2a vector. The pcDNA3-FLNa-GFP, 36 pCl-puro-FLNb-GFP 28 and pEGFP-C3-ASB2a 6 expression constructs have been used previously. Specific silencing of mASB2b was achieved by using an shRNA-expressing vector. Nucleotides 96-114 (sh#1) and 1370-1388 (sh#2) of the mASB2b coding sequence were chosen as target for shRNA. The shRNA sequences were used to construct 60-mer shRNA oligonucleotides, which were then synthesized (MWG) and ligated into the pSUPER.neo.gfp expression vector (Oligoengine) under the control of the H1 promoter. The following oligonucleotides were used (underlined, sense and antisense sequences; boldface, restriction enzyme sites; lightface italics, polIII termination signals; boldface italics, loop with linker): sh#1: 5 0 -GATCCCCGAGTC ATAACGTCTTATAGTTCAAGAGACTATAAGAACGTTATGACTCTTTTTGGAAA-3 0 ; sh#2: 5 0 -GATCCCCCGCCGATGCTAACAAAGCCTTCAAGAGAGGCTTTGTTAG CATCGGCGTTTTTGGAAA-3 0 . All constructs were verified by DNA sequencing.
Northern blotting. Total RNA was isolated from mouse tissues following the method of Chomczynski and Sacchi 37 and from C2C12 cells using a nucleospin RNA II kit (MACHEREY-NAGEL). Hybridization was as described. 38 The ASB2 probe corresponded to the mouse ASB2b open-reading frame. The human RNA Master blot and the mouse embryo MTN blot were obtained from Clontech. PolyA þ RNA samples on Master blot have been normalized to the mRNA levels of eight different 'housekeeping' genes. The b-actin probe was from Clontech and the Arbp probe was previously described as 36B4 probe.
Quantitative RT-PCR. Total mRNAs from human skeletal muscle, heart and smooth muscle were from Clontech. Total mRNA was extracted and purified from NB4 acute promyelocytic leukemia cells treated for 2 days with 10 À6 M all-trans retinoic acid as described. 3 cDNA was synthesized using superscript III first-strand synthesis kit as recommended by the manufacturer (Invitrogen). cDNA synthesis experiments were repeated three times. Real-time PCR was carried out with the 7300 real-time PCR system using the SYBR Green PCR master mix (Applied Biosystems) according to the manufacturer's instructions. The specificity of the PCR primers was confirmed by melting curve analyses. Primers for detection of human ASB2 mRNAs were designed based on chromosome 14 sequence according to the requirements for real-time RT-PCR using the Perl Primer software. Oligonucleotide primer sequences corresponding to distinct exons were as follows: forward 5 0 -AT TCCTGCCTGAAGCC-3 0 and reverse 5 0 -TGCAGTGGACCTGGA-3 0 for ASB2a; forward 5 0 -GAATTGTACCCTTGTTTCAGAG-3 0 and reverse 5 0 -CTCCAGAA CAGACACCC-3 0 for ASB2b; forward 5 0 -GCCCAGAGTGGACAGTTGGA-3 0 and reverse 5 0 -TGGCCTGCGTGTTGATGT-3 0 common to both ASB2 isoforms. Efficiency of amplification was determined using the standard curves method. Fold changes were quantified as 2 À(Ct isoformÀCt common) .
In situ hybridization. In situ hybridization to whole-mount embryos and to tissue sections was performed at various developmental stages, ranging from E2 to E10 as previously described. 39 The fragment corresponding to part of the coding sequence of chicken ASB2 was isolated from pcDNA3-cASB2 and used to generate a single-stranded antisense digoxigenin-labeled RNA probe.
Transfections. Exponentially growing HeLa and NIH3T3 cells were transfected using the Jet PEI reagent (Polyplus transfection) as recommended by the manufacturer. For transient expression, C2C12 cells were transfected using Lipofectamine as per manufacturer's instructions. To establish stable transfectants, we transfected C2C12 cells using the nucleofector V solution and the B32 program, as recommended by the manufacturer (Amaxa). ASB2b knockdown was obtained transfecting C2C12 cells with shRNA against mouse ASB2b. Cells were then cultured for 48 h before selection with 0.5 mg/ml G418 (Invitrogen). FLNb knockdown was obtained transfecting C2C12 cells that have been previously transfected with sh#2 directed against ASB2b with an shRNA against mouse FLNb in pGIPZ vector (Open Biosystems). A vector expressing an shRNA in pGIPZ vector targeted to luciferase (Open Biosystems) was used as a control. After 2 days, we selected the transfected cells using 1 mg/ml puromycin together with 0.5 mg/ml G418.
Whole-cell extracts. C2C12 cells were washed twice in PBS and resuspended in whole-cell extract buffer containing 50 mM Tris-HCl (pH 7.9), 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, 10% glycerol, 1 mM dithiothreitol, 1 mM Na 3 VO 4 , 50 mM NaF and 1% protease inhibitor cocktail (P8340; Sigma-Aldrich). After three freeze-thaw cycles in liquid nitrogen, we cleared the resulting cell lysates by a 10-min 20 000 Â g centrifugation at 41C.
Analysis of detergent soluble, detergent insoluble and urea soluble fractions. Cells (10 6 ) were collected and washed twice in ice-cold PBS. Cell pellets were lysed in 100 ml detergent-soluble fraction (DSF) buffer containing 10 mM Tris-HCl (pH 7.5), 1% Triton X-100, 5 mM EDTA and supplemented with 1 mM Na 3 VO 4 , 50 mM NaF and 1% protease inhibitor cocktail. Insoluble material was recovered by centrifugation at 16 000 Â g for 15 min at 41C. Pellets were then washed with supplemented DSF buffer, resuspended in 20 ml detergent-insoluble fraction (DIF) buffer containing 10 mM Tris-HCl (pH 7.5), 1% SDS and supplemented with 1 mM Na 3 VO 4 , 50 mM NaF and 1% protease inhibitor cocktail, incubated for 15 min at room temperature and for 2 min on ice, and sonicated following the addition of 50 ml DSF buffer. After centrifugation at 16 000 Â g for 5 min at 41C, we resuspended the remaining insoluble material in 10 ml 50 mM Tris-HCl (pH 7) containing 8 M urea and sonicated. Equal amounts of each fraction were heated for 15 min at 371C in SDS-PAGE sample buffer and analyzed by SDS-PAGE.
Antibodies. Two peptides, an N-terminal specific to the mouse ASB2b isoform (ISTRGRQRAIGHEE) and a C-terminal common to ASB2a and b proteins (LAPERARLYEDRRS), were synthesized and coupled to keyhole limpet hemocyanin through a cysteine residue added to the C-or N-terminal amino acid of the peptides, respectively (MilleGen). Rabbit sera were collected 6 months after the initial injection (MilleGen). The serum raised against human ASB2 (1PNA) has been described previously. 3 Primary antibodies were anti-MHC (F59), anti-elongin B (FL-118), anti-Rbx2 (N15), anti-Erk2 (C-14), anti-myogenin (F5D; Santa Cruz Biotechnology), anti-troponin T (JLT-12; Sigma-Aldrich), anti-HA (1D1; Euromedex), anti-polyubiquitinylated proteins (FK1; BIOMOL), anti-elongin C (SIIIp15; Transduction Laboratories), anti-FLNc (Kinasource), anti-Flag (F7425; Sigma-Aldrich) and anti-GFP (Rockland). The anti-human FLNa antiserum that cross-reacts with mouse FLNa has been described. 40 Rabbit anti-FLNb and goat anti-FLNb (N-16) were purchased from Chemicon and Santa Cruz Biotechnology, respectively. Secondary antibody anti-mouse, anti-rabbit and anti-goat conjugates with HRP were from Jackson Laboratories.
Immunofluorescence. Cells were fixed in 4% paraformaldehyde in PBS supplemented with 15 mM sucrose and permeabilized with 0.1% Triton X-100. After blocking with 3% BSA in PBS, we performed immunostaining of cells using antibodies to FLNb from Chemicon in 1 : 1000 and to troponin T in 1 : 1000. Secondary antibodies used were Alexa Fluor 546 or 488 coupled to goat anti-rabbit or goat anti-mouse (Invitrogen). For nuclear staining, we incubated fixed cells with 0.4 mM DAPI for 5 min after secondary antibody incubation. Preparations were mounted in Mowiol (Calbiochem).
Ubiquitylation assays. Recombinant baculoviruses encoding mASB2b, mASB2bL595A and Rbx2 were generated with the BacPAK baculovirus expression system (Clontech). In vitro ubiquitylation assays were carried out as described. 5 FLNb ubiquitylation assays were performed using immunopurified FLNb-GFP as substrate in the presence of the NEDD8 machinery as described. 6 Briefly, NIH3T3 cells were transfected for 24 h with FLNb-GFP expression vector. Anti-GFP antibodies immobilized onto Protein A Sepharose were added to the cell protein extract in a binding buffer adjusted to 20 mM Tris-HCl (pH 7.5), 150 mM NaCl and 0.1% NP-40. After 2 h of incubation on ice and after three washes with binding buffer, we eluted proteins with 100 mM phosphate buffer (pH 12.5) and buffered to pH 8.5 for in vitro ubiquitylation assays. Reaction products were fractionated by SDS-PAGE and analyzed by immunoblotting with anti-GFP antibodies.
